Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: A meta-analysis

Table 1 Baseline characteristics of included trials

Ref.	Country	Design	Treatment	No. pts	Age (yr)	Sex	Tumor size	Tumor number	Child-Pugh class	Virus infection	BCLC stage	ECOG status
						(M/F)	(cm)	(single/multiple)	(A/B/C)	(HBV/HCV)	(A/B/C/D)	(0/1/2)
Moreno-Luna et al[16]	United States	Clinical study	TARE-90Y	61	64 (29-88)	49/12	5.0 (3.3-8.4)	13/48	53/8/0	0/8	12/34/15/0	51/7/1
(2013)			TACE	55	66 (46-84)	43/12	5.0 (3.2-8.5)	20/35	44/11/0	0/7	23/13/19/0	40/15/0
Nicolini et al[21] (2013)	Italy	Clinical study	DEB-TACE	22	57.2 ± 6.5	19/3	1.8 (0.7-4.5)	8/14	NA	8/10	14/8/0/0	NA
			TACE	16	55.6 ± 6.5	15/1	2.2 (1-10)	8/8	NA	3/12	7/9/0/0	NA
Song et al[12] (2012)	South Korea	Cohort study	DEB-TACE	60	61.7 ± 9.8	42/18	4.2 ± 2.8	26/34	56/4/0	44/8	27/33/0/0	NA
			TACE	69	59.0 ± 11.2	48/21	5.0 ± 3.1	31/38	62/6/0	46/8	28/41/0/0	NA
Salem et al[17] (2011)	United States	Clinical study	TARE-90Y	123	66 (30-88)	87/36	4.5 (3.1-6.6)	55/68	67/54/2	13/42	43/65/13/2	NA
			TACE	122	61 (33-88)	102/20	3.6 (2.6-5.7)	57/65	67/53/2	12/56	47/61/12/2	NA
van Malenstein et al[13]	Belgium	RCT	DEB-TACE	16	67.3 ± 9.8	14/2	NA	4/12	14/2/0	4/4	2/9/5/0	9/7/0
(2011)			TACE	14	56.6 ± 13.4	11/3	NA	1/13	14/0/0	4/0	1/10/3/0	10/2/2
Carr et al[19] (2010)	United States	Cohort study	TARE-90Y	99	NA	70/29	NA	NA	NA	9/30	NA	NA
			TACE	691	NA	518/173	NA	NA	NA	97/132	NA	NA
Malagari et al[22]	Greece	RCT	DEB-TACE	41	70.7 ± 6.9	31/10	8.3 ± 2.7	12/29	23/18/0	NA	NA	26/15/0
(2010)			TACE	43	70.0 ± 7.9	34/9	8.1 ± 2.8	15/28	26/17/0	NA	NA	28/15/0
Dhanasekaran et al[14]	United States	Clinical study	DEB-TACE	45	59.9 ± 11.4	35/10	5.5 ± 4.3	21/24	22/11/12	5/20	NA	NA
(2010)			TACE	26	58.9 ± 13.3	19/7	7.4 ± 4.9	10/16	11/11/4	3/11	NA	NA
Nicolini et al[20]	Italy	Clinical study	DEB-TACE	8	57.0 ± 3.8	8/0	3.0 ± 0.9	7/1	5/3/0	0/3	NA	NA
(2010)			TAE	8	56 5 ± 2.0	7/1	3.4 ± 0.2	5/3	6/2/0	2/4	NA	NA
Scartozzi et al[23]	Italy	Clinical study	DEB-TACE	32	68 (41-79)	29/3	NA	NA	14/18/0	NA	NA	NA
(2010)			TACE	50	74 (42-89)	36/14	NA	NA	26/24/0	NA	NA	NA
Kooby et al[18] (2010)	United States	Cohort study	TARE-90Y	27	58.7 ± 10.8	23/4	7.4 ± 3.2	12/15	13/14/0	0/10	NA	NA
			TACE	44	61.0 ± 9.9	36/8	7.4 ± 5.1	25/19	22/22/0	0/25	NA	NA
Lewandowski et al[15]	United States	Clinical study	TARE-90Y	43	68 (44-88)	38/5	NA	20/23	24/19/0	NA	0/34/9/0	NA
(2009)			TACE	43	65 (36-89)	36/7	NA	23/10	23/18/2	NA	0/37/4/2	NA
Ahmad et al[24] (2005)	United States	Clinical study	TARE-90Y	24	61 (40-82)	20/4	NA	NA	NA	5/19	NA	NA
			TACE	52	57 (19-80)	46/6	NA	NA	NA	19/28	NA	NA

RCT: Randomized Controlled trial; TRAE: Transarterial radioembolization; 90Y: Yttrium-90; DEB: Drug-eluting bead; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NA: Not applicable; BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group.